arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Alto Neuroscience, Inc.

ANRO Health Care Biotechnology: Pharmaceutical Preparations
$35.99
▲ +1.2% Today
as of Sep 4, 16:45 ET
Last 30 days +27.56% Jul 27 → Sep 04
$25.93 $28.80 $31.68 $34.56 $37.43 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$36.17
High
$36.98
Low
$35.45
Volume
$269,934
Avg Vol
$695,634
Mkt Cap
$1.3B
P/E (TTM)
—
Beta
—
52w High
$37.48
52w Low
$3.47
Div Yield
—
Shares Out
$35M

Recent Press Releases & News last 60 days · 10 items

Aug 27 · 21:12 MT Newswires
Alto Neuroscience Promotes Nick Smith to President and CFO
Aug 27 · 20:05 PR Business Wire
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
Aug 16 · 20:07 Simply Wall St.
Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued?
▸ Show all 10 press releases & news Free account →

Overview

52-week range
$3.47
$37
96% of range
Avg surprise (last 3)
-15.6%
Avg reaction (last 2)
-7.2%
0% positive
Latest IV / EM
77%
EM ±12.1% · $35 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-2.44$-1.96$-1.48$-1.00$-0.52 Actual $-1.97Actual $-2.33Actual $-2.44Actual $-0.76Actual $-0.60Actual $-0.62Actual $-0.53Est $-0.59Actual $-0.65Est $-0.57Actual $-0.52Actual $-0.80Est $-0.56Actual $-0.65 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-28M$-24M$-21M$-18M$-15M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.65 — — — — financials
Wed May 13, 2026Mar/2026 $-0.80 $-0.56 -42.9% -50.9% -7.2% earnings
Tue Sep 30, 2025Sep 2025 $-0.52 — — — — financials
Wed Aug 13, 2025Jun/2025 $-0.65 $-0.57 -14.0% — — earnings
Wed May 14, 2025Mar/2025 $-0.53 $-0.59 +10.2% — -7.2% earnings
Mon Sep 30, 2024Sep 2024 $-0.62 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.60 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.76 — — — — financials
Sat Sep 30, 2023Sep 2023 $-2.44 — — — — financials
Fri Jun 30, 2023Jun 2023 $-2.33 — — — — financials
Fri Mar 31, 2023Mar 2023 $-1.97 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-29M$-27M—$-15M$-19M$-16M—$-19M
Net income$-28M$-26M—$-14M$-18M$-15M—$-17M
EPS (diluted)$-0.65$-0.80—$-0.52$-0.65$-0.56—$-0.62

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$244M$264M$176M$138M$148M$161M$168M$182M
Inventory————————
Total current assets$247M$269M$178M$139M$150M$164M$169M$184M
Total assets$254M$276M$185M$147M$158M$172M$178M$192M
Long-term debt$12M$14M$16M$20M$20M$20M$10M$7M
Total liabilities$35M$33M$34M$35M$34M$33M$26M$27M
Total equity$219M$243M$151M$112M$123M$139M$151M$165M

Implied volatility — last 90 days

63%148%233%318%403% Jun 07 — IV 212% · EM ±29.3%Jun 08 — IV 208% · EM ±27.4%Jun 09 — IV 226% · EM ±28.4%Jun 10 — IV 247% · EM ±29.2%Jun 11 — IV 237% · EM ±26.1%Jun 15 — IV 327% · EM ±23.6%Jun 16 — IV 403% · EM ±23.8%Jun 19 — IV 86% · EM ±18.9%Jun 22 — IV 109% · EM ±22.7%Jun 23 — IV 138% · EM ±28.3%Jun 24 — IV 99% · EM ±19.8%Jun 25 — IV 111% · EM ±21.8%Jun 26 — IV 114% · EM ±21.8%Jun 29 — IV 114% · EM ±20.2%Jun 30 — IV 158% · EM ±27.3%Jul 01 — IV 131% · EM ±22.0%Jul 02 — IV 131% · EM ±21.2%Jul 03 — IV 136% · EM ±21.2%Jul 06 — IV 152% · EM ±21.1%Jul 07 — IV 175% · EM ±23.2%Jul 08 — IV 208% · EM ±26.1%Jul 09 — IV 124% · EM ±14.7%Jul 10 — IV 203% · EM ±22.5%Jul 13 — IV 267% · EM ±22.3%Jul 14 — IV 172% · EM ±12.4%Jul 15 — IV 362% · EM ±21.4%Jul 16 — IV 355% · EM ±14.8%Jul 20 — IV 124% · EM ±29.3%Jul 21 — IV 77% · EM ±17.9%Jul 22 — IV 71% · EM ±16.2%Jul 23 — IV 85% · EM ±19.2%Jul 24 — IV 84% · EM ±18.5%Jul 27 — IV 120% · EM ±25.0%Jul 28 — IV 86% · EM ±17.6%Jul 29 — IV 91% · EM ±18.2%Jul 30 — IV 109% · EM ±21.3%Jul 31 — IV 96% · EM ±18.3%Aug 03 — IV 92% · EM ±16.3%Aug 04 — IV 140% · EM ±24.1%Aug 05 — IV 126% · EM ±21.0%Aug 06 — IV 103% · EM ±16.7%Aug 07 — IV 93% · EM ±14.5%Aug 10 — IV 94% · EM ±13.0%Aug 11 — IV 109% · EM ±14.4%Aug 12 — IV 127% · EM ±15.9%Aug 13 — IV 162% · EM ±19.1%Aug 14 — IV 105% · EM ±11.6%Aug 17 — IV 192% · EM ±16.1%Aug 18 — IV 211% · EM ±15.2%Aug 20 — IV 189% · EM ±7.9%Aug 24 — IV 74% · EM ±15.4%Aug 25 — IV 85% · EM ±17.4%Aug 26 — IV 71% · EM ±14.2%Aug 27 — IV 70% · EM ±13.8%Aug 28 — IV 75% · EM ±14.4%Aug 31 — IV 63% · EM ±11.2%Sep 01 — IV 85% · EM ±14.6%Sep 02 — IV 77% · EM ±12.8%Sep 03 — IV 75% · EM ±12.2%Sep 04 — IV 77% · EM ±12.1%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in